Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response
- PMID: 33971345
- DOI: 10.1016/j.autrev.2021.102850
Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response
Abstract
Intravenous immunoglobulin (IVIG) is used to treat several autoimmune and inflammatory diseases, but some patients are refractory to IVIG and require alternative treatments. Identifying a biomarker that could segregate IVIG responders from non-responders has been a subject of intense research. Unfortunately, previous transcriptomic studies aimed at addressing IVIG resistance have failed to predict a biomarker that could identify IVIG-non-responders. Therefore, we used a novel data mining technique on the publicly available transcriptomic data of Kawasaki disease (KD) patients treated with IVIG to identify potential biomarkers of IVIG response. By studying the boolean patterns hidden in the expression profiles of KD patients undergoing IVIG therapy, we have identified new metabolic pathways implicated in IVIG resistance in KD. These pathways could be used as biomarkers to segregate IVIG non-responders from responders prior to IVIG infusion. Also, boolean analysis of the transcriptomic data could be further extended to identify a universal biomarker that might predict IVIG response in other autoimmune diseases.
Keywords: Autoimmune diseases; Biomarkers; Boolean patterns; IVIG; Immune metabolism; Therapy; Transcriptome.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Molecular and immunological biomarkers to predict IVIg response.Trends Mol Med. 2015 Mar;21(3):145-7. doi: 10.1016/j.molmed.2015.01.005. Epub 2015 Feb 10. Trends Mol Med. 2015. PMID: 25680699
-
Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.Eur J Pediatr. 2020 Feb;179(2):257-264. doi: 10.1007/s00431-019-03474-w. Epub 2019 Nov 12. Eur J Pediatr. 2020. PMID: 31713683
-
Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy.Clin Rheumatol. 2021 Dec;40(12):5019-5024. doi: 10.1007/s10067-021-05822-4. Epub 2021 Jun 19. Clin Rheumatol. 2021. PMID: 34148165
-
The state of play in tools for predicting immunoglobulin resistance in Kawasaki disease.Expert Rev Clin Immunol. 2023 Jul-Dec;19(10):1273-1279. doi: 10.1080/1744666X.2023.2238122. Epub 2023 Jul 19. Expert Rev Clin Immunol. 2023. PMID: 37458237 Review.
-
Kawasaki disease: a comprehensive review of treatment options.J Clin Pharm Ther. 2015 Dec;40(6):620-5. doi: 10.1111/jcpt.12334. Epub 2015 Nov 7. J Clin Pharm Ther. 2015. PMID: 26547265 Review.
Cited by
-
FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms.Front Immunol. 2024 Sep 18;15:1323171. doi: 10.3389/fimmu.2024.1323171. eCollection 2024. Front Immunol. 2024. PMID: 39359734 Free PMC article.
-
Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.Front Immunol. 2022 Sep 30;13:901872. doi: 10.3389/fimmu.2022.901872. eCollection 2022. Front Immunol. 2022. PMID: 36248801 Free PMC article.
-
Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment.PLoS One. 2023 Mar 29;18(3):e0283710. doi: 10.1371/journal.pone.0283710. eCollection 2023. PLoS One. 2023. PMID: 36989310 Free PMC article.
-
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.Nat Rev Rheumatol. 2021 Dec;17(12):731-748. doi: 10.1038/s41584-021-00709-9. Epub 2021 Oct 29. Nat Rev Rheumatol. 2021. PMID: 34716418 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical